tiprankstipranks
Shield Therapeutics PLC (GB:STX)
LSE:STX
UK Market
STX
Shield Therapeutics
RESEARCH TOOLSreports
Want to see GB:STX full AI Analyst Report?

Shield Therapeutics (STX) Income Statement

42 Followers

Shield Therapeutics Income Statement

Last quarter (Q4 2025), Shield Therapeutics's total revenue was £28.39M, an increase of 306.50% from the same quarter last year. In Q4, Shield Therapeutics's net income was £―. See Shield Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Dec 24Dec 23Dec 22Jun 22
Total Revenue
£ 50.74M£ 25.18M£ 13.09M£ 5.50M£ 1.52M
Gross Profit
£ 22.38M£ 10.57M£ 4.03M£ 2.00M£ 539.00K
Operating Expenses
£ 32.68M£ 37.80M£ 35.36M£ 27.70M£ 20.49M
Depreciation and Amortization
£ 0.00£ 1.12M£ 1.07M£ 2.87M£ 2.21M
EBITDA
£ -10.30M£ -16.58M£ -30.29M£ -46.07M£ -17.69M
Operating Income
£ -10.30M£ -17.98M£ -31.33M£ -26.39M£ -20.41M
Other Income/Expenses
£ -7.20M£ -2.81M£ -1.04M£ -13.67M£ 498.00K
Pretax Income
£ -17.50M£ -20.78M£ -32.38M£ -40.08M£ -19.91M
Net Income
£ -18.03M£ -21.27M£ -33.29M£ -40.44M£ -19.34M
Per Share Metrics
Basic EPS
£ -0.02£ -0.02£ -0.04£ -0.17£ -0.09
Diluted EPS
£ -0.02£ -0.02£ -0.04£ -0.17£ -0.09
Weighted Average Shares Outstanding
 881.34M 905.20M 722.54M 233.19M 204.41M
Weighted Average Shares Outstanding (Diluted)
 881.34M 905.20M 722.54M 233.19M 204.41M
Currency in GBP

Shield Therapeutics Earnings and Revenue History